Core Viewpoint - Oscar Health's CEO Mark Bertolini maintains that the company will achieve profitability by 2026, despite disappointing Q4 2025 results [2][4]. Financial Performance - In Q4 2025, Oscar Health reported an EPS of -$1.24, missing the estimate of -$0.92 by nearly 35% [3]. - The medical loss ratio (MLR) for Q4 was 95.4%, up from 88.1% the previous year, indicating that Oscar spent 95 cents on medical costs for every dollar of premium collected [3]. - Despite the poor financial results, Oscar's stock rose approximately 9.6% following the Q4 announcement, as investors focused on future profitability [3][8]. 2026 Profitability Guidance - Oscar Health anticipates a significant year-over-year improvement of nearly $750 million in earnings from operations in 2026, targeting earnings from operations of $250 million to $450 million, compared to a loss of $396 million in 2025 [4][8]. - The company aims to reduce the MLR to between 82.4% and 83.4% in 2026, a substantial improvement from Q4's 95.4% [5][8]. Strategic Initiatives - **Lever One: AI-driven Efficiency** Oscar is implementing AI technologies to enhance operational efficiency, with the Agentic AI bot reducing response times by 67% during peak enrollment periods and achieving high accuracy in addressing member inquiries [6]. - **Lever Two: Pricing Discipline** The company has taken a weighted average rate increase of approximately 28% for 2026, accounting for the expiration of enhanced premium tax credits that inflated enrollment with higher-risk members in 2025 [7]. - **Lever Three: Market Share Gains** Oscar Health is positioned to gain market share as CVS Health exits the ACA exchange market, which may provide additional opportunities for growth [8].

Core Viewpoint - Cigna is undergoing a strategic shift in its business model, focusing on rebate-free pharmacy benefit services, which is expected to enhance compliance and reshape public perception of pharmacy benefit managers [1][3]. Group 1: Price Target Adjustment - Piper Sandler has reduced its price target for Cigna from $374 to $370 while maintaining an Overweight rating, emphasizing the importance of the rebate-free pharmacy benefit services model in Cigna's strategy [1]. Group 2: Leadership Transition - Cigna's long-time CEO David Cordani is set to retire and transition to the role of executive chair on July 1, with Brian Evanko, a veteran executive, taking over as CEO [2]. Group 3: Business Model Changes - Cigna is shifting some customers to a model that eliminates after-market discounts (rebates), which management anticipates will pressure margins over the next two years [3]. - The company has previously made significant acquisitions, including the $54 billion purchase of Express Scripts in 2018, and divested its Medicare Advantage business last year [3]. Group 4: Company Overview - Cigna operates as a global health company with two primary growth platforms: Evernorth Health Services and Cigna Healthcare, focusing on coordinated health solutions [4].

Core Insights - Alight, Inc. will participate in upcoming investor conferences, including one-on-one meetings and fireside chats, showcasing its leadership in benefits administration [1] Group 1: Investor Conferences - Alight's CEO, Rohit Verma, will conduct one-on-one meetings at the Bank of America Securities Information and Business Services Conference on March 12, 2026, in New York City [1] - The company will also participate in the KeyBanc Capital Markets Healthcare Forum on March 18, 2026, with a fireside chat scheduled for 11:15 am ET, accessible via a live webcast [1] Group 2: Company Overview - Alight, Inc. is a leading provider of health, wealth, leave, and point solutions, serving over 30 million people and many of the world's largest organizations [1] - The Alight Worklife® platform enables employers to better understand and engage their workforce through personalized benefits management and data-driven insights, enhancing employee wellbeing and productivity [1] Group 3: Financial Performance - For the full year 2025, Alight reported revenue of $2.3 billion, alongside strong cash flow from operating activities and free cash flow [1]

Economic Data Summary - The U.S. economy lost 92,000 jobs in the latest report, with the previous month's job numbers revised down to 126,000 from 130,000, indicating a total payroll revision of -69,000 over two months [1][2][5] - The unemployment rate increased to 4.4%, raising concerns about the strength of the labor market amidst rising oil prices [5][8] - Private payrolls decreased by 86,000, with manufacturing payrolls down by 12,000, suggesting weakness in these sectors [2][9] Retail Sales Insights - Retail sales headline figures dropped by 0.2%, while the control group saw a slight increase of 0.3% after a flat reading in December, indicating only a modest improvement in retail sales [3][4] - The retail sales data for January was delayed due to the government shutdown, which may affect the interpretation of current trends [2][3] Market Reactions - Equity futures fell across the board, with the S&P 500 down by 0.8%, reflecting negative sentiment in response to the labor market data [4] - The commodity market remained stable, with WTI closing at $86 and Brent at $89, despite the concerning employment figures [4][5] Sector-Specific Developments - The healthcare sector experienced a significant decline, losing 34,000 jobs, partly due to a strike involving 31,000 workers at Kaiser Health Insurance [9][10] - Construction jobs decreased by 11,000, which may have been influenced by weather conditions, contrasting with expectations of a rise [10]

Core Viewpoint - Elevance Health, Inc. is under investigation for potential securities fraud and unlawful business practices following a notification from the Centers for Medicare & Medicaid Services regarding sanctions on its Medicare Advantage plans [1][2]. Group 1: Investigation Details - Pomerantz LLP is investigating claims on behalf of Elevance investors, focusing on possible securities fraud or unlawful business practices by the company and its officers [1]. - The investigation was prompted by a recent disclosure from Elevance about sanctions from CMS, which may affect its Medicare Advantage-Prescription Drug plans [2]. Group 2: CMS Sanctions - On March 2, 2026, Elevance announced that CMS intends to impose sanctions that would suspend enrollment of Medicare beneficiaries into its MA-PD plans and halt certain communications with these beneficiaries [2]. - The sanctions are related to alleged noncompliance with Medicare Advantage risk adjustment data submission requirements for services prior to April 3, 2023, and are set to take effect on March 31, 2026, unless resolved [2]. - Following this announcement, Elevance's stock price dropped by $25.93, or 8.1%, closing at $294.07 per share on the same day [2].

Core Viewpoint - Humana Inc. has announced a public offering of $1.0 billion in junior subordinated notes, which are set to close on March 9, 2026, pending customary closing conditions [1]. Group 1 - The offering consists of fixed-to-fixed rate junior subordinated notes due in 2056, priced at 100.000 percent of the principal amount [1]. - The company anticipates net proceeds from the offering, although specific figures for the net proceeds are not disclosed [1].

Core Viewpoint - Oscar Health, Inc. (OSCR) is showing potential for a bullish trend as it has recently broken above the 50-day moving average, indicating a key level of support [1]. Group 1: Technical Indicators - The 50-day simple moving average is a significant marker for traders and analysts to identify support or resistance levels, and OSCR's recent breakout suggests a short-term bullish trend [2]. - Over the past four weeks, OSCR shares have increased by 13.8%, indicating positive momentum [2]. Group 2: Earnings Estimates - Positive revisions in earnings estimates for OSCR strengthen the bullish outlook, with no estimates decreasing in the past two months and three estimates increasing [3]. - The consensus estimate for OSCR has also risen, further supporting the case for potential growth [3]. Group 3: Investment Consideration - Given the technical indicators and positive earnings estimate revisions, OSCR is recommended for investors to consider adding to their watchlist [3].

Core Insights - Alight, Inc. has announced a strategic collaboration with VB Scout to enhance the value of voluntary benefits through claims integration technology [1] - The integration aims to help employees capture the full value of their voluntary benefits coverage by providing proactive notifications for eligible claims [1] - VB Scout's technology has shown to increase claims paid by 30-45% and improve loss ratios by up to 10% through notification-based outreach [1] Company Overview - Alight, Inc. is a leading benefits administration provider serving over 30 million people, focusing on health, wealth, leave, and point solutions [1] - VB Scout is a technology company that specializes in voluntary benefits claims integration, utilizing big data to enhance the benefits experience for various stakeholders [1] Technology and Impact - The collaboration will integrate VB Scout's claims integration engine, which synthesizes medical claims data, voluntary benefits plan documents, and employee eligibility files [1] - This technology identifies claims that qualify for reimbursement under various voluntary benefit policies, including accident and critical illness coverage [1] - The partnership aims to close the gap between voluntary benefits enrollment and actual utilization by ensuring employees are informed about their eligibility [1] Analytics and Decision-Making - The collaboration provides powerful analytics for employers, brokers, and carriers, enabling better benchmarking of plan value and tracking of loss ratios [1] - VB Scout's Identified Claims Value reporting allows stakeholders to assess the performance of voluntary benefit plans relative to qualified claims [1] - Insights gained from this collaboration will support informed decision-making to optimize outcomes for both employees and employers [1]

Core Insights - Bank of America's US1 list includes top stock picks that provide significant passive income through dividends, appealing to investors seeking reliable income streams, especially those nearing retirement [1][2] Group 1: Bank of America US1 List Overview - The US1 list is curated from Buy-rated, US-listed stocks, aiming for superior long-term investment performance [1] - The list features five stocks with substantial upside potential and reliable dividends, appealing to investors amid a sustained market rally [1] Group 2: Featured Stocks - **America Healthcare REIT (AHR)**: Offers a 1.89% dividend, focusing on clinical healthcare real estate, with a price target of $60 set by Bank of America [1] - **Cigna Group (CI)**: Provides tailored health insurance and employee benefits, yielding 2.08% with a price target of $378 [1] - **Merck (MRK)**: A global healthcare leader with a 2.67% dividend, involved in pharmaceuticals and animal health, with a price target of $132 [2] - **Public Service Enterprise Group (PEG)**: A utility stock yielding 2.98%, operating in New Jersey with a price target of $84 [2] - **Wells Fargo (WFC)**: A financial services company with a 2.06% dividend yield, serving over 70 million customers globally, with a price target of $107 [2]

Core Insights - Clover Health Investments (CLOV) is positioned for growth due to its technology-first care model, evidenced by membership growth, rising revenues, and sustained adjusted EBITDA profitability, although it faces challenges from elevated medical costs and execution risks [1][7]. Financial Performance - Clover's shares have decreased by 25.6% over the past six months, while the industry has declined by 34.3%, and the S&P 500 has increased by 7.2% [2]. - The company has a market capitalization of $1.05 billion and projects a 39.8% earnings growth for Q1 2026 [2]. - Clover reported $22 million in adjusted EBITDA for 2025 and anticipates $50-$70 million for 2026 [5][9]. Membership and Ratings - Clover experienced a 38% year-over-year increase in Medicare Advantage enrollment, reaching over 113,803 members, with a 4.4% sequential increase [4][7]. - The company earned a 4-Star rating from CMS for its PPO plan, which covers over 95% of its members, qualifying it for higher quality bonus payments [4]. Strategic Initiatives - Clover aims to achieve GAAP net income profitability in 2026, guiding for net income between breakeven and $20 million [9]. - The company is focusing on improving member unit economics through cost-efficient acquisition channels and optimizing Part D initiatives [10]. Challenges - Clover's Insurance Benefit Expense Ratio (BER) was reported at 90.9% in 2025, a 970 basis-point increase year-over-year, indicating pressure on insurance margins [13]. - The company faces regulatory and policy dependence, with potential impacts from changes in Medicare funding and reimbursement dynamics due to recent legislation [16][17]. Technology and Growth - Clover's differentiation relies on its Clover Assistant and expansion into Counterpart Health, with a focus on deepening physician adoption and translating clinical engagement into economic benefits [18][19]. - The company aims to maintain leadership in New Jersey and scale its technology platform, targeting parity between Counterpart Assistant and Clover Assistant lives managed [12].